| 000 | 01567 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250516161737.0 | ||
| 264 | 0 | _c20140321 | |
| 008 | 201403s 0 0 eng d | ||
| 022 | _a1473-6322 | ||
| 024 | 7 |
_a10.1097/01.all.0000433132.16436.b5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMouthon, Luc | |
| 245 | 0 | 0 |
_aManagement of secondary immune deficiencies: what is the role of immunoglobulins? _h[electronic resource] |
| 260 |
_bCurrent opinion in allergy and clinical immunology _cJul 2013 |
||
| 300 |
_aS56-67 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Blocking _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadverse effects |
| 650 | 0 | 4 |
_aAutoimmune Diseases _xcomplications |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 |
_aHematologic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunologic Deficiency Syndromes _xetiology |
| 650 | 0 | 4 |
_aImmunosuppression Therapy _xadverse effects |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aFermand, Jean-Paul | |
| 700 | 1 | _aGottenberg, Jacques-Eric | |
| 773 | 0 |
_tCurrent opinion in allergy and clinical immunology _gvol. 13 Suppl 2 _gp. S56-67 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.all.0000433132.16436.b5 _zAvailable from publisher's website |
| 999 |
_c22935320 _d22935320 |
||